{"id":868788,"date":"2025-07-11T08:20:06","date_gmt":"2025-07-11T12:20:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/"},"modified":"2025-07-11T08:20:06","modified_gmt":"2025-07-11T12:20:06","slug":"cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/","title":{"rendered":"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated<\/li>\n<li>Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer\u2019s disease<\/li>\n<\/ul>\n<p>\u200dBOSTON, July  11, 2025  (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer&#8217;s Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025.<\/p>\n<p>\n        <strong><br \/>\n          <em>Details of the poster presentations at AAIC 2025 are as follows:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics (#106386)<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Session Date\/Time:<\/strong>\u00a0Monday, July 28, 2025, 7:30 a.m. \u2013 4:15 p.m. ET<\/li>\n<\/ul>\n<p>\n        <strong>Title:<\/strong>\u00a0NETSseq unveils deep molecular insights into astrocyte function in Alzheimer\u2019s disease in the human brain (#106433)<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Session Date\/Time:<\/strong>\u00a0Wednesday, July 30, 2025, 7:30 a.m. \u2013 4:15 p.m. ET<\/li>\n<\/ul>\n<p>\n        <strong>About NETSseq<\/strong><br \/>\n        <br \/>Our proprietary platform, <strong>N<\/strong>uclear <strong>E<\/strong>nriched <strong>T<\/strong>ranscript <strong>S<\/strong>ort <strong>seq<\/strong>uencing (NETSseq), enables the identification of subtle molecular changes that drive disease progression. By analyzing brain tissue from a diverse pool of over 20,000 donors, ranging in age from 8 to 104, and including both healthy individuals and those with various central nervous system (CNS) disorders, NETSseq allows us to identify targets that are expressed at very low levels, are present in rare cell types, or change over time as a disease progresses. This transformative tool provides deep insights into the molecular drivers of disease within specific cell populations, expanding our understanding and treatment of neurodegenerative diseases. It enables us to pursue therapies that directly address underlying disease mechanisms. Our platform has been instrumental in the development of our investigational assets, forming a cornerstone of our innovative approach to CNS drug discovery.<\/p>\n<p>\n        <strong>About CVN293<\/strong><br \/>\n        <br \/>CVN293 is an investigational, highly selective oral inhibitor of the potassium two pore domain channel subfamily K member 13 (KCNK13). By selectively inhibiting KCNK13, a potentially novel regulator of NLRP3 inflammasome activation, CVN293 aims to reduce neuroinflammation and slow disease progression in a variety of neurodegenerative disorders. This mechanism may provide a disease-modifying approach for challenging CNS disorders. Additionally, modulation of KCNK13 may have therapeutic benefit in obesity. KCNK13 was identified by Cerevance\u2019s proprietary NETSseq platform.<\/p>\n<p>\n        <strong>About Cerevance<\/strong><br \/>\n        <br \/>Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative and central nervous system-controlled metabolic disorders. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both the motor and non-motor symptoms of Parkinson&#8217;s disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting KCNK13. CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aZ6bT3QS_8pPk47Ij08y07QV9E4qGXnVB3fEACrKh-g9YIA9tbNM51yBayW7HDRymHrVbggAcHnVNzzP8r7vROzrUGT-ajhJeQB8ObGVwwA=\" rel=\"nofollow\" target=\"_blank\">www.cerevance.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8IoUzyDWTrgXmmckBDTTZCSWrRcqogot_8srW2-QL3XEmfcxD9-YJ0c3h6L_nUiXGpx26sLFvfIK3s4qKgsBAparNNq2v3Roe2f4GEsP8IU=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W0yXUlONSjBMDprF32gsKPDjwy1fH_5gRuAx6P6QGJv7fQsq1Fq4_6GEbVLLI46NJdo2RIDF_nqaharjAYwZ9w==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Contacts\u00a0<\/strong>\n      <\/p>\n<p>\n        <strong>Cerevance:\u00a0<\/strong><br \/>\n        <br \/>Johnna Sim\u00f5es, ir@cerevance.com<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>April Dovorany, adovorany@realchemistry.com, +1-262-909-8739<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDZiOTk4NzAtM2JlYS00OTFjLWI0NTktOTNmNzI0ZDBhMTMzLTEzMTAxMDctMjAyNS0wNy0xMS1lbg==\/tiny\/Cerevance-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer\u2019s disease \u200dBOSTON, July 11, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer&#8217;s Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025. Details of the poster presentations at AAIC 2025 are as follows: Title:\u00a0CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics (#106386) Session Date\/Time:\u00a0Monday, July 28, 2025, 7:30 a.m. \u2013 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868788","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerevance Announces Presentations at the Alzheimer&#039;s Association International Conference 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerevance Announces Presentations at the Alzheimer&#039;s Association International Conference 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer\u2019s disease \u200dBOSTON, July 11, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer&#8217;s Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025. Details of the poster presentations at AAIC 2025 are as follows: Title:\u00a0CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics (#106386) Session Date\/Time:\u00a0Monday, July 28, 2025, 7:30 a.m. \u2013 &hellip; Continue reading &quot;Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T12:20:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025\",\"datePublished\":\"2025-07-11T12:20:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/\"},\"wordCount\":508,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/\",\"name\":\"Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\",\"datePublished\":\"2025-07-11T12:20:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Market Newsdesk","og_description":"Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer\u2019s disease \u200dBOSTON, July 11, 2025 (GLOBE NEWSWIRE) &#8212; Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer&#8217;s Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025. Details of the poster presentations at AAIC 2025 are as follows: Title:\u00a0CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics (#106386) Session Date\/Time:\u00a0Monday, July 28, 2025, 7:30 a.m. \u2013 &hellip; Continue reading \"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-11T12:20:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025","datePublished":"2025-07-11T12:20:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/"},"wordCount":508,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/","name":"Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=","datePublished":"2025-07-11T12:20:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTY2NiM3MDM1NjAyIzIyOTg1NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevance-announces-presentations-at-the-alzheimers-association-international-conference-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cerevance Announces Presentations at the Alzheimer&#8217;s Association International Conference 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868788"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868788\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}